Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent Pharmaceuticals, a specialty pharmaceutical company, has received FDA approval for Bacitracin for injection, USP, an anti-infective product used to treat pneumonia and empyema.
Subscribe to our email newsletter
Sagent Pharma said that Bacitracin for injection will be offered in a 50,000 MU, preservative-free, latex-free, single-dose vial packaged both individually and in packages of 10. The vials will feature Sagent’s proprietary PreventIV Measures labeling and packaging, with distinctive labeling designs and easy to read drug name and dosage information.
Bacitracin marks the seventh product approved from Sagent Pharma’s partnership with Strides Arcolab. Under this venture, Sagent Pharma and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the US market. Strides is responsible for developing and manufacturing injectable products that Sagent will market in the US.
Jeffrey Yordon, founder, chairman and CEO of Sagent Pharma, said: “Including Bacitracin, our anti-infective product line now encompasses nine products. To provide pharmacies of all types with the flexibility they require to stock Bacitracin appropriate to their individual needs, Sagent Pharma will offer the product in both single units and in convenient packs of ten.”